Athersys (ATHX) Misses Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/24/2026
- Wall St set for higher open after tech rout; Mideast, tariffs in focus
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil retreats from above $100, still set for weekly rise on Middle East escalation
- Meta’s new seller app hits eBay where it hurts most
- Pullback in chip stocks is a buying opportunity, Citi says
Athersys Reports First Quarter 2020 Results
May 7, 2020 4:05 PM EDTManagement to host conference call at 4:30 pm EDT today
CLEVELAND--(BUSINESS WIRE)-- Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended March 31, 2020.
Highlights of the first quarter of 2020 and recent events include:
Received authorization from the U.S. Food and Drug Administration (FDA) to initiate a Phase 2/3 COVID-19 induced acute respiratory distress syndrome (ARDS) clinical trial; completed site initiation and began enrolling patients in this trial referred to as the MACOVIA study; Received FDA authorization to... More